Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
A double punch against SARS-CoV-2
Monoclonal antibodies are an important weapon in the battle against COVID-19. However, these large proteins are difficult to produce in the needed quantities and at low cost. Attention has turned to nanobodies, which are aptly named, single-domain antibodies that are easier to produce and have the potential to be administered by inhalation. Koenig et al. describe four nanobodies that bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent infection of cells (see the Perspective by Saelens and Schepens). Structures show that the nanobodies target two distinct epitopes on the SARS-CoV-2 spike protein. Multivalent nanobodies neutralize virus much more potently than single nanobodies, and multivalent nanobodies that bind two epitopes prevent the emergence of viral escape mutants.
Science
, this issue p.
Top-30
Citations by journals
2
4
6
8
10
12
|
|
Frontiers in Immunology
12 publications, 3.79%
|
|
Nature Communications
11 publications, 3.47%
|
|
International Journal of Molecular Sciences
7 publications, 2.21%
|
|
Viruses
7 publications, 2.21%
|
|
Scientific Reports
5 publications, 1.58%
|
|
mAbs
5 publications, 1.58%
|
|
Communications Biology
4 publications, 1.26%
|
|
International Journal of Biological Macromolecules
4 publications, 1.26%
|
|
iScience
4 publications, 1.26%
|
|
Proceedings of the National Academy of Sciences of the United States of America
4 publications, 1.26%
|
|
Cells
3 publications, 0.95%
|
|
Frontiers in Molecular Biosciences
3 publications, 0.95%
|
|
Signal Transduction and Targeted Therapy
3 publications, 0.95%
|
|
Cell Reports
3 publications, 0.95%
|
|
Antiviral Research
3 publications, 0.95%
|
|
Advanced Science
3 publications, 0.95%
|
|
Journal of the American Chemical Society
3 publications, 0.95%
|
|
EMBO Reports
3 publications, 0.95%
|
|
PLoS Pathogens
3 publications, 0.95%
|
|
Microorganisms
2 publications, 0.63%
|
|
Vaccines
2 publications, 0.63%
|
|
Frontiers in Microbiology
2 publications, 0.63%
|
|
Nature
2 publications, 0.63%
|
|
Journal of Nanobiotechnology
2 publications, 0.63%
|
|
Journal of Biological Chemistry
2 publications, 0.63%
|
|
Nano Today
2 publications, 0.63%
|
|
Virologica Sinica
2 publications, 0.63%
|
|
Current Opinion in Virology
2 publications, 0.63%
|
|
Structure
2 publications, 0.63%
|
|
2
4
6
8
10
12
|
Citations by publishers
10
20
30
40
50
60
70
|
|
Cold Spring Harbor Laboratory
62 publications, 19.56%
|
|
Elsevier
55 publications, 17.35%
|
|
Springer Nature
51 publications, 16.09%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
26 publications, 8.2%
|
|
Frontiers Media S.A.
21 publications, 6.62%
|
|
Wiley
19 publications, 5.99%
|
|
American Chemical Society (ACS)
18 publications, 5.68%
|
|
EMBO press
6 publications, 1.89%
|
|
Public Library of Science (PLoS)
6 publications, 1.89%
|
|
Taylor & Francis
6 publications, 1.89%
|
|
Oxford University Press
6 publications, 1.89%
|
|
American Association for the Advancement of Science (AAAS)
6 publications, 1.89%
|
|
American Society for Microbiology
5 publications, 1.58%
|
|
Proceedings of the National Academy of Sciences (PNAS)
4 publications, 1.26%
|
|
Royal Society of Chemistry (RSC)
3 publications, 0.95%
|
|
American Society for Biochemistry and Molecular Biology
2 publications, 0.63%
|
|
KeAi Communications Co.
2 publications, 0.63%
|
|
Microbiology Society
1 publication, 0.32%
|
|
NEJM Group
1 publication, 0.32%
|
|
Portland Press
1 publication, 0.32%
|
|
Dove Medical Press
1 publication, 0.32%
|
|
Walter de Gruyter
1 publication, 0.32%
|
|
Cambridge University Press
1 publication, 0.32%
|
|
Rockefeller University Press
1 publication, 0.32%
|
|
American Institute of Mathematical Sciences (AIMS)
1 publication, 0.32%
|
|
eLife Sciences Publications
1 publication, 0.32%
|
|
Scientific Scholar
1 publication, 0.32%
|
|
Bentham Science
1 publication, 0.32%
|
|
Spandidos Publications
1 publication, 0.32%
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.